Pages that link to "Q38540135"

The following pages link to Tackling Crizotinib Resistance: The Pathway from Drug Discovery to the Pediatric Clinic (Q38540135):

Displaying 12 items.

• The ALK/ROS1 Inhibitor PF-06463922 Overcomes Primary Resistance to Crizotinib in ALK-Driven Neuroblastoma (Q27853241) (← links)
• Novel ALK inhibitor AZD3463 inhibits neuroblastoma growth by overcoming crizotinib resistance and inducing apoptosis. (Q27853323) (← links)
• Second- and third-generation ALK inhibitors for non-small cell lung cancer (Q28072496) (← links)
• Quantification and pharmacokinetics of crizotinib in rats by liquid chromatography-tandem mass spectrometry (Q35807581) (← links)
• Treatment of a chemoresistant neuroblastoma cell line with the antimalarial ozonide OZ513. (Q36184684) (← links)
• Novel MDM2 inhibitor SAR405838 (MI-773) induces p53-mediated apoptosis in neuroblastoma (Q37696208) (← links)
• Novel multiple tyrosine kinase inhibitor ponatinib inhibits bFGF-activated signaling in neuroblastoma cells and suppresses neuroblastoma growth in vivo (Q37701501) (← links)
• ALK gene alterations in cancer: biological aspects and therapeutic implications (Q38767006) (← links)
• Oral Metronomic Topotecan Sensitizes Crizotinib Antitumor Activity in ALKF1174L Drug-Resistant Neuroblastoma Preclinical Models. (Q40999620) (← links)
• Long-term progression-free survival in an advanced lung adenocarcinoma patient harboring EZR-ROS1 rearrangement: a case report (Q49404537) (← links)
• Glycogen synthase kinase 3 controls migration of the neural crest lineage in mouse and Xenopus. (Q51738187) (← links)
• Genomics of adult and pediatric solid tumors (Q58804574) (← links)